



(51) International Patent Classification:

A61K 31/352 (2006.01) A61K 31/46 (2006.01)
A61K 31/381 (2006.01) A61K 31/4745 (2006.01)
A61K 31/382 (2006.01) A61P 3/10 (2006.01)

(21) International Application Number:

PCT/US2013/020051

(22) International Filing Date:

3 January 2013 (03.01.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/584,526 9 January 2012 (09.01.2012) US

(71) Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, MSC 7660, Bethesda, Maryland 20892-7660 (US).

(72) Inventors: NECKERS, Leonard M.; 5121 Wissioming Road, Bethesda, Maryland 20816 (US). SOURBIER, Carole; 6070 California Circle, #413, Rockville, Maryland 20852 (US). LINEHAN, W. Marston; 7007 Tilden Lane, North Bethesda, Maryland 20852 (US). NECKERS, Jane B.; 5121 Wissioming Road, Bethesda, Maryland 20816 (US). LEE, Min-Jung; 10506 Prairie Landing Ter., North Potomac, Maryland 20878 (US). SCROGGINS, Bradley T.; 445 Elmcroft Blvd., Apt. 8306, Rockville, Maryland 20850 (US). BEUTLER, John A.; 9131 Liberty Village Way, Union Bridge, Maryland 21791 (US).

(74) Agents: PILLAI, Xavier et al.; LEYDIG, VOIT & MAYER, LTD., Two Prudential Plaza, Suite 4900, 180 North Stetson Avenue, Chicago, Illinois 60601 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

7 April 2016

(54) Title: METHODS OF TREATING OR PREVENTING INSULIN RESISTANCE AND ASSOCIATED DISEASES AND CONDITIONS



(57) Abstract: Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (HSF1), or inducing the expression of heat shock protein 70 (HSP70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (I) or an epimer thereof, wherein Ar, and R¹-R⁶ are described herein. Examples of diseases or conditions associated with insulin resistance include diabetes, obesity, inflammation, metabolic syndrome, polycystic ovary disease, arteriosclerosis, non-alcoholic fatty liver disease, reproductive abnormality in a female, and growth abnormality.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2013/020051

A. CLASSIFICATION OF SUBJECT MATTER
 INV. A61K31/352 A61K31/381 A61K31/382 A61K31/46 A61K31/4745
 A61P3/10
 ADD.
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EPO-Internal, BIOSIS, EMBASE, FSTA, INSPEC, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HAASCH D ET AL: "PKCtheta is a key player in the development of insulin resistance", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 343, no. 2, 5 May 2006 (2006-05-05), pages 361-368, XP024923484, ACADEMIC PRESS INC. ORLANDO, FL, US ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2006.02.177 [retrieved on 2006-05-05] page 361, abstract ----- -/--	1-23

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 5 February 2016	Date of mailing of the international search report 23/02/2016
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Baurand, Petra
--	---

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2013/020051

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SOURBIER C. ET AL.: "Abstract 959: Targeting renal cell carcinoma with englerin A", CANCER RESEARCH, vol. 71, 15 April 2011 (2011-04-15), XP002753931, AACR 102nd Annual Meeting 2011 - Apr 2 - 6; Orlando, FL abstract	1-23
A	----- RATNAYAKE RANJALA ET AL: "Englerin A, a Selective Inhibitor of Renal Cancer Cell Growth, from Phyllanthus engleri", ORGANIC LETTERS, vol. 11, no. 1, 1 January 2009 (2009-01-01), pages 57-60, XP002517710, AMERICAN CHEMICAL SOCIETY, US ISSN: 1523-7060, DOI: 10.1021/OL802339W [retrieved on 2008-12-05] table 2	1-23
A	----- WO 2009/088854 A1 (US HEALTH [US]; BEUTLER JOHN A [US]; RATNAYAKE RANJALA [US]; COVELL DA) 16 July 2009 (2009-07-16) cited in the application claims 4,19 -----	1-23

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2013/020051

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2009088854	A1	16-07-2009	
		AU 2008347299 A1	16-07-2009
		CA 2711434 A1	16-07-2009
		DK 2235021 T3	08-10-2012
		EP 2235021 A1	06-10-2010
		ES 2393877 T3	28-12-2012
		JP 5547653 B2	16-07-2014
		JP 2011508779 A	17-03-2011
		US 2010286259 A1	11-11-2010
		WO 2009088854 A1	16-07-2009
